Ric Fordham
4 Papers
Ric Fordham is an academic researcher. The author has contributed to research in topics: Internal medicine & Logistic regression. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Correction: The Minderoo-Monaco Commission on Plastics and Human Health
Philip J Landrigan,Hervé Raps,Maureen Cropper,Caroline Bald,Manuel Brunner,Elvia Maya Canonizado,Dominic Charles,Thomas C. Chiles,Mary J. Donohue,Judith Enck,Patrick Fenichel,Lora E. Fleming,Christine Ferrier-Pagès,Ric Fordham,Aleksandra Gozt,Carly Griffin,Mark E. Hahn,Budi Haryanto,Richard Trombone Hixson,Hannah Ianelli,Bryan D. James,Pushpam Kumar,Amalia Laborde,Kara Lavender Law,Keith Martin,Jenna Mu,Yannick R. Mulders,Adetoun Mustapha,Jia Niu,Sabine Pahl,Yongjoon Park,Maria Luiza Pedrotti,Jordan Avery Pitt,Mathuros Ruchirawat,Bhedita J. Seewoo,Margaret Spring,John J. Stegeman,William Suk,C N Symeonides,Hideshige Takada,Richard C. Thompson,Andrea Vicini,Zhanyun Wang,Elizabeth Whitman,David Wirth,Megan J. Wolff,Aroub Yousuf,Sarah Dunlop +47 more
TL;DR: The article details a correction to a previously published article on the Minderoo-Monaco Commission on Plastics and Human Health.
9
Was Alpha deadlier than wild-type COVID? Analysis in rural England
Julii Brainard,Carlota Maria Grossi Sampedro,Anna Sweeting,Ric Fordham +3 more
TL;DR: The Alpha variant of SARS-CoV-2 did not lead to higher mortality rates for any age, deprivation or sex group, compared to case fatality rates in the early part of the pandemic period as mentioned in this paper .
Rituximab compared to intravenous cyclophosphamide in adults with connective tissue disease-associated interstitial lung disease: the RECITAL RCT
Toby M Maher,Veronica A Tudor,Peter Saunders,Fernando Zanghelini,Carlota Maria Grossi Sampedro,Georgios Xydopoulos,M. Gibbons,Sophie V Fletcher,C. P. Denton,Maria Kokosi,Rachel K. Hoyles,Helen Parfrey,Elisabetta Renzoni,A. Wells,Deborah Ashby,Ric Fordham,Matyas Szigeti,Philip L. Molyneaux +17 more
TL;DR: This Phase IIb RCT compares rituximab to cyclophosphamide in adults with severe, progressive connective tissue disease-associated interstitial lung disease, finding no significant difference in forced vital capacity improvement between the two treatments.
Cost-Effectiveness of GaitSmart and an Artificial Intelligence Solution for Rehabilitation of Patients Undergoing Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) in Older Population in the United Kingdom
F. Zanghelini,Aisling Ponzo,Georgios Xydopoulos,Ric Fordham,Saval Khanal +4 more
TL;DR: This study evaluates the cost-effectiveness of GaitSmart, a sensor-based rehabilitation device, for patients undergoing total hip or knee arthroplasty in the UK, finding it to be a dominant intervention with cost savings and improved quality-adjusted life years.